Cytotoxic T Cell Response Against the Chimeric ETV6-AML1 Protein in Childhood Acute Lymphoblastic Leukemia

Overview

Journal J Clin Invest

Specialty General Medicine

Date 1998 Jul 17

PMID 9664088

Citations 40

Authors

P Yotnda

F Garcia

M Peuchmaur

B Grandchamp

M Duval

F Lemonnier

E Vilmer

P Langlade-Demoyen

Affiliations

Soon will be listed here.

Abstract

Cytotoxic T lymphocytes (CTL) are potent effector cells that could provide long term antitumor immunity if induced by appropriate vaccines. CTL recognize 8-14 amino acid-long peptides processed intracellularly and presented by MHC class I molecules. A well-characterized example of a potential tumor antigen in childhood pre-B Acute Lymphoblastic Leukemia (ALL) results from the chromosomal translocation 12;21 leading to the fusion of the ETV6 and AML1 genes. This translocation is observed in > 25% of ALL-patients. In this study, we have examined whether the chimeric ETV6-AML1 protein could serve as a tumor specific antigen for CTL in HLA-A2.1 individuals. We have identified a nonapeptide (RIAECILGM), encoded by the fusion region of the ETV6-AML1 protein, that binds to HLA-A2.1 molecules and induces specific primary CTL in peripheral blood lymphocytes from healthy donors. These CTL specifically lysed HLA-A2.1 tumor cells endogeneously expressing the ETV6-AML fusion protein. CTL with similar functional capacities were found with high frequencies and cloned from one patient's bone marrow indicating that ETV6-AML1-specific anti-ALL CTL are, at least in some patients, spontaneously stimulated and might participate to host antileukemia defense.

Citing Articles

Tumor microenvironment antigens.

Andersen M Semin Immunopathol. 2022; 45(2):253-264.

PMID: 36175673 PMC: 10335965. DOI: 10.1007/s00281-022-00966-0.

Therapeutic Cancer Vaccines-Antigen Discovery and Adjuvant Delivery Platforms.

Alarcon N, Jaramillo M, Mansour H, Sun B Pharmaceutics. 2022; 14(7).

PMID: 35890342 PMC: 9325128. DOI: 10.3390/pharmaceutics14071448.

Therapeutic Vaccines against Hepatocellular Carcinoma in the Immune Checkpoint Inhibitor Era: Time for Neoantigens?.

Reparaz D, Aparicio B, Llopiz D, Hervas-Stubbs S, Sarobe P Int J Mol Sci. 2022; 23(4).

PMID: 35216137 PMC: 8875127. DOI: 10.3390/ijms23042022.

Identification of neoantigens for individualized therapeutic cancer vaccines.

Lang F, Schrors B, Lower M, Tureci O, Sahin U Nat Rev Drug Discov. 2022; 21(4):261-282.

PMID: 35105974 PMC: 7612664. DOI: 10.1038/s41573-021-00387-y.

Neoantigen Controversies.

Castro A, Zanetti M, Carter H Annu Rev Biomed Data Sci. 2021; 4:227-253.

PMID: 34465181 PMC: 10146390. DOI: 10.1146/annurev-biodatasci-092820-112713.

References

Rosenberg S, Lotze M . Cancer immunotherapy using interleukin-2 and interleukin-2-activated lymphocytes. Annu Rev Immunol. 1986; 4:681-709. DOI: 10.1146/annurev.iy.04.040186.003341. View

Agape P, Gerard B, Cave H, Devaux I, Vilmer E, Lecomte M . Analysis of ETV6 and ETV6-AML1 proteins in acute lymphoblastic leukaemia. Br J Haematol. 1997; 98(1):234-9. DOI: 10.1046/j.1365-2141.1997.1973014.x. View

Falk K, Rotzschke O, Stevanovic S, Jung G, Rammensee H . Allele-specific motifs revealed by sequencing of self-peptides eluted from MHC molecules. Nature. 1991; 351(6324):290-6. DOI: 10.1038/351290a0. View

Tsomides T, Walker B, Eisen H . An optimal viral peptide recognized by CD8+ T cells binds very tightly to the restricting class I major histocompatibility complex protein on intact cells but not to the purified class I protein. Proc Natl Acad Sci U S A. 1991; 88(24):11276-80. PMC: 53117. DOI: 10.1073/pnas.88.24.11276. View

Gavrieli Y, Sherman Y, Ben-Sasson S . Identification of programmed cell death in situ via specific labeling of nuclear DNA fragmentation. J Cell Biol. 1992; 119(3):493-501. PMC: 2289665. DOI: 10.1083/jcb.119.3.493. View

Bertoletti A, Chisari F, Penna A, Guilhot S, Galati L, Missale G . Definition of a minimal optimal cytotoxic T-cell epitope within the hepatitis B virus nucleocapsid protein. J Virol. 1993; 67(4):2376-80. PMC: 240403. DOI: 10.1128/JVI.67.4.2376-2380.1993. View

Andersson K, Deggerdal A, Skjonsberg C, Smeland E, Blomhoff H . Constitutive expression of c-myc does not relieve cAMP-mediated growth arrest in human lymphoid Reh cells. J Cell Physiol. 1993; 157(1):61-9. DOI: 10.1002/jcp.1041570108. View

Connan F, Hlavac F, Hoebeke J, Guillet J, Choppin J . A simple assay for detection of peptides promoting the assembly of HLA class I molecules. Eur J Immunol. 1994; 24(3):777-80. DOI: 10.1002/eji.1830240344. View

Celis E, Tsai V, Crimi C, Demars R, Wentworth P, Chesnut R . Induction of anti-tumor cytotoxic T lymphocytes in normal humans using primary cultures and synthetic peptide epitopes. Proc Natl Acad Sci U S A. 1994; 91(6):2105-9. PMC: 43318. DOI: 10.1073/pnas.91.6.2105. View

10.

Golub T, Barker G, Lovett M, Gilliland D . Fusion of PDGF receptor beta to a novel ets-like gene, tel, in chronic myelomonocytic leukemia with t(5;12) chromosomal translocation. Cell. 1994; 77(2):307-16. DOI: 10.1016/0092-8674(94)90322-0. View

11.

Kawakami Y, Eliyahu S, Sakaguchi K, Robbins P, Rivoltini L, Yannelli J . Identification of the immunodominant peptides of the MART-1 human melanoma antigen recognized by the majority of HLA-A2-restricted tumor infiltrating lymphocytes. J Exp Med. 1994; 180(1):347-52. PMC: 2191573. DOI: 10.1084/jem.180.1.347. View

12.

Boel P, Wildmann C, Sensi M, Brasseur R, Renauld J, Coulie P . BAGE: a new gene encoding an antigen recognized on human melanomas by cytolytic T lymphocytes. Immunity. 1995; 2(2):167-75. DOI: 10.1016/s1074-7613(95)80053-0. View

13.

Romana S, Poirel H, Leconiat M, Flexor M, Mauchauffe M, Jonveaux P . High frequency of t(12;21) in childhood B-lineage acute lymphoblastic leukemia. Blood. 1995; 86(11):4263-9. View

14.

Harada M, Matsunaga K, Oguchi Y, Iijima H, Ito O, Tamada K . The involvement of transforming growth factor beta in the impaired antitumor T-cell response at the gut-associated lymphoid tissue (GALT). Cancer Res. 1995; 55(24):6146-51. View

15.

Shurtleff S, Buijs A, Behm F, Rubnitz J, Raimondi S, Hancock M . TEL/AML1 fusion resulting from a cryptic t(12;21) is the most common genetic lesion in pediatric ALL and defines a subgroup of patients with an excellent prognosis. Leukemia. 1995; 9(12):1985-9. View

16.

Raynaud S, Cave H, Baens M, Bastard C, Cacheux V, Grosgeorge J . The 12;21 translocation involving TEL and deletion of the other TEL allele: two frequently associated alterations found in childhood acute lymphoblastic leukemia. Blood. 1996; 87(7):2891-9. View

17.

Quesnel A, Hsu S, Delmas A, Steward M, Trudelle Y, Abastado J . Efficient binding to the MHC class I K(d) molecule of synthetic peptides in which the anchoring position 2 does not fit the consensus motif. FEBS Lett. 1996; 387(1):42-6. DOI: 10.1016/0014-5793(96)00446-2. View

18.

Cayuela J, Baruchel A, Orange C, Madani A, Auclerc M, Daniel M . TEL-AML1 fusion RNA as a new target to detect minimal residual disease in pediatric B-cell precursor acute lymphoblastic leukemia. Blood. 1996; 88(1):302-8. View

19.

Dethlefs S, Escriou N, Brahic M, van der Werf S . Theiler's virus and Mengo virus induce cross-reactive cytotoxic T lymphocytes restricted to the same immunodominant VP2 epitope in C57BL/6 mice. J Virol. 1997; 71(7):5361-5. PMC: 191774. DOI: 10.1128/JVI.71.7.5361-5365.1997. View

20.

Anderson P, Nagler-Anderson C, OBrien C, Levine H, Watkins S, Slayter H . A monoclonal antibody reactive with a 15-kDa cytoplasmic granule-associated protein defines a subpopulation of CD8+ T lymphocytes. J Immunol. 1990; 144(2):574-82. View